Societies

Paolo Tarantino: More than 25 ASCO24 oral presentations by Dana-Farber Cancer Institute researchers

Photo from Paolo Tarantino/X

May 31, 2024, 15:41

Paolo Tarantino: More than 25 ASCO24 oral presentations by Dana-Farber Cancer Institute researchers

Paolo Tarantino shared a post by Dana-Farber Cancer Institute on X:

“More than 25 ASCO24 oral presentations by Dana-Farber Cancer Institute researchers, including Antonio Giordano presenting on the Nectin4 ADC enfortumab vedotin for metastatic breast cancer and Ana Garrido-Castro presenting the first randomized Topo1 ADC-IO trial in breast oncology!” .

Quoting Dana-Farber Cancer Institute’s post:

“Heading to ASCO24? There are more than 25 oral presentations that are Dana-Farber researcher lead. Check out the list and follow Dana Farber News for full conference coverage.”

Paolo Tarantino

Source: Paolo Tarantino/X and Dana-Farber Cancer Institute/X

Ana Garrido-Castro Antonio Giordano ASCO24 breast oncology cancer Dana-Farber Cancer Institute Dana-Farber News Enfortumab vedotin metastatic breast cancer Nectin4 ADC OncoDaily Oncology Paolo Tarantino

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer